Feasibility of Radical Prostatectomy After Neoadjuvant Chemohormonal Therapy for Patients With High Risk or Locally Advanced Prostate Cancer: Results of a Phase I/II Study
- 1 February 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 171 (2) , 709-713
- https://doi.org/10.1097/01.ju.0000108122.36893.5a
Abstract
We determined the feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy in locally advanced (stage T3 or greater) and/or high risk tumors (Gleason 8 to 10 and/or serum prostate specific antigen (PSA) greater than 20 ng/ml). Enrollment criteria included clinical stage T1 to 2 with any Gleason grade and PSA greater than 20 ng/ml, clinical stage T3 to 4 with any serum PSA or Gleason grade, or any clinical stage with biopsy Gleason grade of 8 to 10 and any serum PSA. All patients received neoadjuvant hormonal therapy during chemotherapy (4 cycles of paclitaxel and carboplatin and estramustine) followed by radical prostatectomy. Nerve sparing was decided on an individual basis and a nerve graft was offered to those who underwent unilateral or bilateral nerve resection. Perioperative morbidity, mortality and delayed complications were assessed. A total of 36 patients were enrolled. After chemohormonal therapy clinical stage was less in 39% of patients and greater in 36%. Bilateral nerve sparing was performed in 3 patients and the remaining 33 underwent either unilateral or bilateral neurovascular bundle resection with nerve grafts performed in 17 (52%). Deep vein thrombosis (22%) was the most frequent complication of chemotherapy. Minor postoperative complications occurred in 6 patients. At a median followup of 29 months (range 5 to 51) after radical prostatectomy 32 (89%) were continent and 5 (15%) preoperatively potent men remained potent. The positive surgical margin rate was 22%. Of all subjects 45% remain free from biochemical recurrence. Neoadjuvant chemohormonal therapy followed by radical prostatectomy can be performed with low morbidity. Positive surgical margin rates are low. This approach yielded good local control of disease, however impact on tumor recurrence and survival is not known.Keywords
This publication has 18 references indexed in Scilit:
- Paclitaxel, Estramustine Phosphate, and Carboplatin in Patients With Advanced Prostate CancerJournal of Clinical Oncology, 2001
- Results of a Phase II Study Using Estramustine Phosphate and Vinblastine in Combination With High-Dose Three-Dimensional Conformal Radiotherapy for Patients With Locally Advanced Prostate CancerJournal of Clinical Oncology, 2000
- The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U. S.Cancer, 1998
- Treatment of Breast CancerNew England Journal of Medicine, 1998
- PROGRESSION IN AND SURVIVAL OF PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER (T3) TREATED WITH RADICAL PROSTATECTOMY AS MONOTHERAPYJournal of Urology, 1998
- Randomized, Prospective, Controlled Study Comparing Radical Prostatectomy Alone and Neoadjuvant Androgen Withdrawal in the Treatment of Localized Prostate CancerJournal of Urology, 1996
- Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockage in Clinical Stage B2 (T2bNxM0) Prostate CancerJournal of Urology, 1995
- The treatment of prostate cancer by conventional radiation therapy: An analysis of long-term outcomeInternational Journal of Radiation Oncology*Biology*Physics, 1995
- SERUM PSA AFTER ANATOMIC RADICAL PROSTATECTOMYUrologic Clinics of North America, 1993
- Prognostic factors in prostate cancer: Analysis of 874 patients treated with radiation therapyCancer, 1993